Blog
RSS FeedPosted by Michael Wonder on 03 Mar 2020
The coronavirus could help pharma reset its reputation in Washington
3 March 2020 - The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington. ...
Posted by Michael Wonder on 03 Mar 2020
'Get it done. We need it': Trump's coronavirus message to big pharma
3 March 2020 - President Donald Trump sought to show his personal engagement in the fight against coronavirus, meeting with ...
Posted by Michael Wonder on 06 Jan 2020
Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals
3 January 2020 - A federal judge dealt the pharmaceutical industry a setback by declining to block a new California ...
Posted by Michael Wonder on 19 Dec 2019
North America trade pact deals rare setback to big pharma
19 December 2019 - A revamped North American trade deal nearing passage in Congress gives both the White House and ...
Posted by Michael Wonder on 10 Dec 2019
Do large pharma companies provide drug development innovation? Our analysis says no.
10 December 2019 - Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. ...
Posted by Michael Wonder on 26 Nov 2019
Teva, drug makers in talks with U.S. to end generics probes
26 November 2019 - Deferred prosecution agreements among resolutions discussed. ...
Posted by Michael Wonder on 22 Nov 2019
Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years
21 November 2019 - International reference pricing provisions in plan would decimate development of innovative medicines by nearly 90%. ...
Posted by Michael Wonder on 26 Oct 2019
Public sector financial support for late stage discovery of new drugs in the United States: cohort study
23 October 2019 - This study determined the extent to which late stage development of new drugs relies on support from ...
Posted by Michael Wonder on 17 Oct 2019
Pelosi’s drug pricing plan puts medical innovation at risk
17 October 2019 - The future of medical innovation in America is at a crossroads. ...
Posted by Michael Wonder on 11 Oct 2019
Pharma industry is 'right in the crosshairs,' Merck CEO Kenneth Frazier says
11 October 2019 - President Donald Trump and House Speaker Nancy Pelosi are in a battle over impeachment but their ...
Posted by Michael Wonder on 08 Oct 2019
FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
8 October 2019 - The U.S. FDA today announced that it has awarded 12 new clinical trial research grants totaling ...
Posted by Michael Wonder on 14 Sep 2019
Right to try ‘remains a bust,’ as many drug makers prefer FDA reviews
12 September 2019 - Despite the hubbub over the “right-to-try” law, a recent survey found that nearly half of drug ...
Posted by Michael Wonder on 12 Sep 2019
Big Pharma is abusing patents, and it's hurting Americans
12 September 2019 - The American patent system has, since our nation's founding, served as a cornerstone of innovation. But ...
Posted by Michael Wonder on 29 Aug 2019
Are reasonable restraints on drug price increases doomed by pharma lobbying?
29 August 2019 - In a rare but important display of congressional bipartisanship, Senators Chuck Grassley (R-Iowa) and Ron Wyden ...
Posted by Michael Wonder on 28 Aug 2019
Placebos and blinding in randomised controlled cancer clinical trials for drug and biological products: guidance for industry
28 August 2019 - This guidance provides recommendations to industry about the use of placebos and blinding in randomised controlled clinical ...